Table 1.
Demographic details of RRMS patients and healthy controls.
| Treatment group | Healthy controls | w/o | IFN-β | Natalizumab | Fingolimod |
|---|---|---|---|---|---|
| n | 21 | 11 | 18 | 16 | 24 |
| Sex [w/m] | 15/6 | 7/4 | 16/2 | 11/5 | 17/7 |
| Age [mean] | 40.4 | 37.5 | 39.9 | 36.5 | 39.2 |
| Age [range] | 22.1–55.6 | 23.5–53.8 | 23.3–59.36 | 23.9–53.2 | 26.0–53.08 |
| In relapse/remission [n] | n/a | 11/0 | 5/13 | 7/9 | 8/16 |
| Disease duration [years, mean] | n/a | 6.0 | 7.2 | 7.2 | 11.9 |
| Disease duration [years, range] | n/a | 0–14.7 | 0.1–18.7 | 1.2–14.4 | 1.69–32.0 |
| EDSS [mean, n] | n/a | 1.5, n = 2 | 2.9, n = 7 | 2.8, n = 8 | 3.8, n = 16 |
| EDSS [range] | n/a | 1–2 | 2–4 | 1–7.5 | 2–6.5 |
Disease duration of 0 indicates blood sampling at initial diagnosis. Missing data: The EDSS score was not evaluated on the date of sample preparation in all cases. n/a, not available, w/o, RRMS patients without therapy.